Praxis Precision Medicines, Inc. - Common Stock · Transaction Jul 30, 2026 · Filed Sep 4, 2026 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · PRAX
+0.38% · +$1.14 · Vol Not reported
Pre-market · updated 04:15:52 ET
Praxis Precision Medicines Inc
Biotechnology
$300.01
Follow $PRAX
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $PRAX by emailVeridion Score
BETAMEDIUM CONF · 5 of 6 factors measuredMon Sep 21 · last completed session · Pre-market · regular session opens 9:30 ET · PRAX
MethodologySentiment absence reason unknown
PRAX
Praxis Precision Medicines Inc
Mon Sep 21 · last completed session · Pre-market · regular session opens 9:30 ET
Upper range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
66/ 100
Veridion Score
Upper range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5 of 6 factors measured · Mon Sep 21 · last completed session · Pre-market · regular session opens 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is PRAX moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Praxis Precision Medicines Inc
PHARMACEUTICAL PREPARATIONSListed since
2020
Employees
11K
Country
US
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$298.87
Last session
Day high
$298.87
Last session
Day low
$298.87
Last session
Previous close
$298.87
52W high
$386.33
-22.34% from high
52W low
$48.33
74% of range
Market cap
$8.3B
EPS
$-12.7400
Beta
0.68
Shares out
27.9M
Avg volume
371.2K
VWAP
$298.87
Last session
Price history computed in-house
1W
-4.12%
1M
-20.20%
3M
-2.89%
1Y
+520.75%
YTD
+1.79%
SMA 50 $338.15 · below
SMA 200 $314.89 · below
52W position 74%
PRAX overview
Related filings and maps
Public disclosures
Congress activity in PRAX
Official filing ↗
Federal contracts
PRAX contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for PRAX in this window.
Lobbying spend
PRAX lobbying filings, year to date.
Registered lobbying filings matched to Praxis Precision Medicines Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for PRAX in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for PRAX.
Options
Sovereign unlock shows live options positioning for PRAX.